Non-beta lactam antibiotics (oxadiazoles)


The newly discovered oxadiazole class of antibiotics  impairs cell-wall biosynthesis and exhibits activities against the Gram-positive bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. They are efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance.  This class of antibiotics hold great promise in recourse against infections by MRSA

Patent Information:
For Information, Contact:
Richard Cox
Director, Technology Commercialization
University of Notre Dame
(574) 631-5158
Mayland Chang
Shahriar Mobashery
Edward Spink
Derong Ding
Sebastian Testero
Erika Leemans
Marc Boudreau
© 2018. All Rights Reserved. Powered by Inteum